Our medical advisory team brings over 150 years of Hepatitis related experience to this project. Our team consists of medical practitioners from many disciplines, all dedicated to finding a cure for Hepatitis B and C, and improving the quality of life for the Chronic liver Disease patients. Until a cure is discovered, our focus is on developing ever more effective strategies to encourage healthy liver structure and function. At the present time, our best approach is embodied by our three-pronged management system: Diet, a proper lifestyle including daily exercise, and a liver-targeted supplement system to help to maintain optimal liver health.
Our team is directed by one common goal: as independent medical practitioners (and practicing medical doctors), they are all committed to finding a cure for Hepatitis B and C. However they all agree that in the meantime the use of a proven three pronged management system may be their patient’s best option.
DR. PETER SCHMID
Peter Schmid, M.D. also holds a degree in engineering from the Federal Engineering Institute, Austria.
Before he moved to the United States, where he held a position as assistant Professor at the University of Vienna Hospital, Internal Medicine and Surgery Departments, he made a variety of medical technical inventions and conducted/published research mainly in the field of metabolism and nutrition. At this time Dr. Schmid also became a certified specialist in Internal Medicine.
He was invited to the United States by the University of Southern California in 1979 to the position of Research Associate Professor, to work with Bernhard Strehler in the field of aging research. Dr. Strehler was at this time considered one of the world’s foremost researchers in this field. He was the key figure in the installation of the National Institute of Aging, a part of NIH, giving testimony to congress regarding the need for an independent Institute of Aging research, which bolstered the position and funding of the Gerontology Research Institute in Baltimore, the largest and best funded aging research laboratory worldwide at this time. Nevertheless, Dr. Strehler was invited by USC to receive his laboratory at the Molecular Biology Institute of USC, where Dr. Schmid joined him to collaborate in several projects.
In 1982 Dr. Schmid moved his position to the University of California Molecular Biology Institute in Los Angeles where he conducted Research project in the field of Cancer Molecular Biology – in particular oncogenes - and later, in the Department of Neurology at UCLA, he began to work on the elucidation of viral etiology and pathogenesis of Neurological disorders like Multiple Sclerosis, Herpes Encephalopathy and Aids Dementia complex.
His realization that the molecular tools for the detection of viruses were not at the optimal level needed for the ultra-sensitive detection and quantification of viruses in human tissues and body liquids, in particular blood, lead to several key inventions in the field of molecular detection technology that later played a key role in the development of therapies against viral diseases like AIDS and hepatitis B and C as well as cancer detection. Furthermore the plasma product industry and the blood supply were in critical need of Nucleic Acid Based detection technologies at extreme sensitivity worldwide, to reduce the alarming rate of infections caused by blood products and blood, a situation in which Dr. Schmid's technologies suddenly became of highest importance.
To make these inventions and technologies available at an industrial scale for the purpose of new drug development and also the screening of infected blood donations for viral contamination, Dr. Schmid, together with two partners, founded the National Genetics Institute that was based solely on Dr. Schmid's inventions. Among many other projects, all the large-scale registration trials that moved forward the drug treatment of hepatitis C with Interferon and Ribavirin used Dr. Schmid's methodology of automated ultra high sensitivity PCR. He also worked intensively in the field of Hepatitis B drug development and on the development of PCR based cancer cell detection in white blood cells and lymph nodes. He also was actively interested in the field of therapeutic vaccines for hepatitis B and C and had a particular interest in thymic peptides and adjuvants used for therapeutic vaccines. Further research interests include the measurement and quantification of liver fibrosis by noninvasive methodology and the Molecular Biology of fibrogenesis, which was applied to fibrogenesis in the liver.
DR. LORNE TYRRELL
"It is not hyperbole to write that there are few scientists who have done as much to advance the health of those infected with hepatitis B virus as Dr. Tyrrell." - Dr. Timothy Block, president of the Hepatitis B Foundation at the Pennsylvania Institute for Hepatitis and Virus Research.
Dr. Lorne Tyrrell has helped shape policy in education, healthcare, and health research. He is the current CIHR/GlaxoSmithKline Chair in Virology at the University of Alberta and the Chief Scientific Officer of KMT, a biotechnology company in Edmonton. Dr. Tyrrell is the Chair of the Board of the Health Quality Council of Alberta, Chair of the Board of the Institute of Health Economics, a Board Member of the Gairdner Foundation, and a member of the Research Council of the Canadian Institute of Advanced Research. In 2004, Dr. Tyrrell completed 10 years as the Dean of the Faculty of Medicine and Dentistry at the University of Alberta.
Dr. Tyrrell has won numerous awards at the University of Alberta (Rutherford Undergraduate Teaching Award, J. Gordin Kaplan Research Awards, and the University Cup). He won the ASTech Award for Research in 1993, the national Prix Galien award in 1998 and was awarded the Gold Medal of the Canadian Liver Foundation in 2000.
Dr. Tyrrell was appointed to the Alberta Order of Excellence in 2000, an Officer of the Order of Canada in 2002, and a Fellow of the Royal Society of Canada in 2004. He was recently awarded the F.N.G. Starr Award from the Canadian Medical Association in 2004, and the Principal Award of the Manning Foundation in 2005 for his work on the development of oral antivirals for the treatment of HBV.
A gifted teacher, he continues to teach virology to students, and to pursue research on both Hepatitis B and C, with the ultimate goal of curing these diseases.
DR. BRADFORD WEEKS
Bradford S. Weeks, M.D. is a well-known authority in Corrective Health whole clinical protocols as they are practiced around the world. In addition to caring for patients suffering from degenerative illnesses at his clinic on Whidbey Island in Washington State, Dr. Weeks frequently lectures to physicians regarding his comprehensive psycho-neuro-immunological corrective protocols. His therapeutic strategies featuring nutritional biochemistry (replenishment and detoxification) as well as targeted treatment protocols for killing viri or cancers while enhancing immune status. Dr. Weeks is also a well-known consultant for Health and Performance Enhancement for the executive management teams of numerous domestic and international corporations.
Dr. Weeks completed undergraduate studies at Dartmouth College. Then, prior to medical school training at the University of Vermont, Dr. Weeks worked in the Harvard system doing two years of research at Massachusetts General Hospital's mineral metabolism unit working on osteoporosis and vitamin D). In addition, he studied nutrition (including macrobiotics with Mishio Kushi in Brookline, MA), acupuncture, Anthroposophical medicine and classical homeopathy. Medical school at the University of Vermont was followed by medical internship (1 year) and psychiatric residency at Dartmouth Hitchcock Medical Center (3 years). Dr. Weeks is a general practitioner with a specialization in psychiatry (particularly the role of psycho-neuro-immunology) but has developed and advanced the field of corrective medicine and psychiatry in order to care for patients suffering with cancer, hepatitis and other degenerative illnesses.
Dr. Weeks was named Orthomolecular Physician of the Year in 2003 and was awarded the SmithKline Beecham Young Investigator Award in 1986. The topics of his publications and lectures are myriad covering topics such as sleep disorders, mineral metabolism, proteolytic enzyme therapy, corrective cancer care, endocrinology and infectious diseases.
DR. THOMAS ABSHIER
Dr. Abshier practices as a licensed Naturopathic Physician (ND) in Portland Oregon where he has maintained a general family practice including internal medicine and counseling for the past 28 years. Dr. Abshier graduated from National College of Naturopathic Medicine in 1987 after pursuing a wide range of life and educational experiences including: a Bachelor of Science from the UCLA School of Engineering, Naval Nuclear Power School and submarine service as a US Naval officer, and various businesses before pursuing his career in Naturopathic Medicine. He has maintained a general medical practice, including: hormone therapy, chronic disease, weight loss, heart disease, diabetes, cancer, and mental health. Anyone who has had the privilege of working with Dr. Abshier as a physician will soon note his caring heart, and his commitment to understanding the cause and mechanisms producing disease and health. His analytical mind and approach to natural medicine make him well suited for membership in the HepTech team where he bridges the worlds of business, medical practitioners/researchers, and nature-cure physicians.
ROB CAPARINI, CLINICAL PHARMACIST
Rob Caparini received his Bachelor of Science Degree in Cellular, Molecular and Microbial Biology in 1990 from the University of Calgary. He worked at a pharmaceutical research facility in Calgary Alberta before entering the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta. He graduated with the degree of BSc Pharmacy in 1994 and has been a hospital based Clinical Pharmacist since 1995, specializing in the area of Infectious Disease Therapy.
IN MEMORIAM: DR. CHARLES LIEBER, M.D., M.A.C.P., F.A.C.G.
(Feb. 13, 1931 to March 1, 2009) Honorary Lifetime Medical Advisory Position
We are honoring Dr. Charles S. Lieber’s lifetime work of study, the advancement of PPC and the treatment of Cirrhosis from alcoholism, by furthering his clinical work and continuing to advance his cirrhotic theories.
Dr. Lieber devoted much of his career to advancing the understanding of the pathogenesis of alcoholic liver disease and, consequently potential therapies to treat this chronic condition. Dr. Lieber was born in Antwerp, Belgium, on Feb. 13, 1931. He earned his medical degree in 1955 at the University of Brussels "He was a giant in his field, probably the most eminent in the world in alcohol and the liver,” said Dr. Steven Schenker, another expert, at the University of Texas Health Science Center at San Antonio. He was 78 and lived in Englewood Cliffs, N.J when he passed away after battling stomach cancer.
Dr. Charles S. Lieber is recognized as an expert on liver diseases, nutrition, and the toxicology of alcohol. A native of Antwerp, Belgium, Dr. Lieber received his undergraduate and graduate education at the University of Brussels, where he was awarded his M.D. degree in 1955 as the top ranking student. After working as a research assistant in the Dept of Pharmacology and receiving training in Internal Medicine and Gastroenterology at the University of Brussels, he acquired expertise in Liver Disease and Nutrition as an Instructor and Associate at Harvard University Medical School and Boston City Hospital from 1958 to 1963. He then moved to Cornell University Medical College as Associate Professor of Medicine and Director of the Liver Disease and Nutrition Unit at Bellevue Hospital, New York City. In 1968, he joined Mount Sinai School of Medicine to become Professor of Medicine and Pathology, and Chief of Liver Disease and Nutrition at the Bronx Veterans Affairs Medical Center. There he also directed the Alcohol Dependence Treatment Program and the Alcohol Research Center. Since 1960, he has trained over 200 postdoctoral fellows in the fields of gastroenterology, liver disease and nutrition.
His achievements include the discovery of a new, alcohol-inducible, pathway for ethanol metabolism in liver microsomes involving a unique form of cytochrome P450 (now called CYP2E1). It explains interactions of ethanol with other drugs and the vulnerability of drinkers to the hepatotoxicity of commonly used medications (e.g. acetaminophen), anesthetics, industrial solvents and carcinogens. Ethanol was also found to potentiate the toxicity of vitamin A and β-carotene, partly by inducing newly discovered pathways of retinol metabolism. Several metabolic effects of ethanol were uncovered such as hyperuricemia, ketosis, increased blood HDL and high acetaldehyde levels, with their hepatic and extrahepatic pathological consequences. Respective roles of toxic and dietary factors in the pathogenesis of alcoholic liver disease were elucidated: it was shown that even in the absence of dietary deficiencies, alcohol produces hepatic fat accumulation and ultrastructural alterations in man and cirrhosis in non-human primates; the latter was prevented by polyenylphosphatidylcholine, now being evaluated clinically in patients with hepatic fibrosis. Perivenular fibrosis was identified as a precirrhotic lesion. Dr. Lieber also showed that alcohol consumption promotes hepatitis C and he pioneered in the therapeutic use of S-adenosylmethionine to prevent hepatoxicity in the baboon model of alcoholic liver disease. He elucidated the role of gender and gastric alcohol dehydrogenase (ADH) in ethanol oxidation and its inhibition by commonly used drugs. The gene of sigma ADH, a newly recognized gastric isozyme, was cloned and found to explain ethnic differences in the vulnerability to ethanol. He was also the first to use antibiotics to eradicate gastric Helicobacter pylori and the associated ammonia production using antibiotics, with beneficial effects in patients with hepatic encephalopathy or gastritis. Nonalcoholic steatohepatitis (NASH) was reproduced experimentally and beneficial effects of acarbose were discovered.
Dr. Lieber has authored or coauthored 1,023 scientific publications and 12 books. The last available survey of the "Most-Cited Scientist" by the Institute for Scientific Information revealed that he is the most frequently cited scientist (in the field of pathology) worldwide, and one of his articles is among the 10 most cited in 1996-2000. Four of his papers have been selected as Current Contents "Citation Classics" and one as Current Contents "hot" paper, one was published as a "Nutrition Classics" of Nutrition Reviews, and another is one of Alcohol Health and Research World's 16 "Seminal Articles" for the period 1970-1995.
Dr. Lieber received research and service awards from the Dept of Veterans Affairs (W.S. Middleton & Leahy Research), AMA, Am Soc for Clin Nutr (McCollum & Herman), Am Gastroenter Assoc (Distinguished Achievement & Hugh Butt-Fiterman for Clin Res in Hepatology/Nutrition), Alcohol Research (E.M. Jellinek), Res Soc on Alcoholism (Distinguished Achievement & F. Seixas), Am Soc of Addiction Med (Distinguished Scientist), Am Coll of Gastroenter (Stuart & Henry Baker) R. Brinkley Smithers (for research and education on alcohol, alcoholism and their effects on liver and nutrition) and from several other national and international scientific societies. He is a member of the Assoc of Am Phys, the Am Soc for Clin Invest, the AMA, the Am Soc for Biochem and Molec Biol, a Master of the Am Coll of Phys and a Fellow of the Am Institute of Nutr and the Am Coll of Gastroenter. He is a honorary member of the Soc of Toxicology, the Finnish Soc of Gastroenter and the Japanese Med Soc on Alcohol Studies. He founded and has been president of the Res Soc on Alcoholism, president of the Am Soc for Clin Nutr, the Am Soc of Addiction Med and the NY Gastroenter Assoc. He has held 39 Visiting Professorships worldwide, and has been editor or member of the editorial board of 34 professional publications. YR/Bio-5A -02/27/04